Protagonist Therapeutics Inc

NASDAQ:PTGX 4:00:00 PM EDT

26.85

+0.24 (+0.90%)

4:07:25 PM EDT: $26.52 -0.33 (-1.23%)

Market Cap (Intraday)	1.56B
Current PE	N/A
Forward PE	20.34
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$180 Million
Adjusted EPS	$1.19

See more estimates

10-Day MA	$26.65
50-Day MA	$28.42
200-Day MA	$21.79

See more pivots

Protagonist Therapeutics Inc Stock, NASDAQ:PTGX

7707 Gateway Boulevard, Suite 140, Newark, California 94560-1160

United States of America

Phone: +1.510.474.0170

Number of Employees: 112

http://www.protagonist-inc.com

Description

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.